SCHEMBL2833859

SCHEMBL2833859

O=C(O)c1c(CN2CCCC2=O)n(CCC(F)(F)F)c(=O)c2c(F)cccc12

nearest known ligand 0.37

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
BDKRB1 P46663 1/20 0.37
CMA1 P23946 1/20 0.36
POLB P06746 1/20 0.35
KMT2A Q03164 2/20 0.35
TSHR P16473 2/20 0.35
PER2 O15055 2/20 0.34
ADORA2B P29275 1/20 0.33
MEN1 O00255 1/20 0.33
MAPT P10636 1/20 0.33
RECQL P46063 1/20 0.33
HTT P42858 1/20 0.33
L3MBTL1 Q9Y468 1/20 0.33
FABP4 P15090 1/20 0.33
NPC1 O15118 1/20 0.32
RAB9A P51151 1/20 0.32
KDM4E B2RXH2 1/20 0.32
ALDH1A1 P00352 1/20 0.32
GAA P10253 1/20 0.32
SMN1; SMN2 Q16637 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2148916 0.89 BDKRB1 (0.40) BDKRB1POLBKMT2ATSHRPER2
SCHEMBL2830538 0.82 BDKRB1 (0.41) BDKRB1CMA1POLBKMT2ATSHR
SCHEMBL14828546 0.81 SCN9A (0.39) BDKRB1CMA1POLB
SCHEMBL1718109 0.81 L3MBTL1 (0.40) BDKRB1POLBKMT2ATSHRMEN1
SCHEMBL7950603 0.80 TACR3 (0.40) BDKRB1NPC1RAB9A
SCHEMBL2677599 0.79 MEN1 (0.40) BDKRB1CMA1POLBKMT2APER2
SCHEMBL2831883 0.78 BDKRB1 (0.42) BDKRB1POLBKMT2ATSHRMEN1
SCHEMBL2676781 0.78 L3MBTL1 (0.42) BDKRB1POLBKMT2ATSHRPER2
SCHEMBL1717499 0.77 BDKRB1 (0.39) BDKRB1POLBKMT2APER2MEN1
SCHEMBL2830636 0.77 CNR2 (0.38) CMA1POLBKMT2ATSHRPER2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2342182-B1 ISOQUINOLINONE DERIVATIVES AS NK3 ANTAGONISTS LUNDBECK & CO AS H (DK) 2012-11-14 EP claimed
US-8242134-B2 Isoquinolinone derivatives as NK3 antagonists H. LUNDBECK A/S (DK) 2012-08-14 US claimed
US-20100076016-A1 ISOQUINOLINONE DERIVATIVES AS NK3 ANTAGONISTS H. LUNDBECK A/S (DK) 2010-03-25 US claimed
EP-2342182-B1 ISOQUINOLINONE DERIVATIVES AS NK3 ANTAGONISTS LUNDBECK & CO AS H (DK) 2012-11-14 EP disclosed
US-8242134-B2 Isoquinolinone derivatives as NK3 antagonists H. LUNDBECK A/S (DK) 2012-08-14 US disclosed
US-20100076016-A1 ISOQUINOLINONE DERIVATIVES AS NK3 ANTAGONISTS H. LUNDBECK A/S (DK) 2010-03-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100076016-A1 ISOQUINOLINONE DERIVATIVES AS NK3 ANTAGONISTS KCNQ3, KCNK3, GRIK3 BDKRB1 421/4885CMA1 2697/4885POLB 3744/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.